Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Non-invasive prenatal testing for Down's syndrome - beyond the hype

22 June 2015

By Jane Fisher

Director of Antenatal Results and Choices

Appeared in BioNews 807

There has been much recent media interest in non-invasive prenatal testing for Down's syndrome (NIPT) (see BioNews 805), and this coincides with deliberations by the UK National Screening Committee on its potential inclusion in the NHS Down's syndrome screening programme.

The test itself is not so new in the UK. It first became available in the private sector in late 2012, and provision has since proliferated. Thousands of women have been willing to pay between £400 and £1,000 for the test since then. In fact, we can speculate that the recent dip in the number of invasive diagnostic tests performed after Down's syndrome screening is due to women having NIPT (1).

There is enough evidence in the literature, including from large-scale studies (albeit mainly in medium and high-risk populations), to conclude that NIPT is a highly accurate screening test for Down's syndrome, with higher sensitivity and specificity than standard NHS tests (2). In view of this, it is likely to be offered on the NHS as a contingent screen (offered to women who fall within a particular risk assessment after their primary Down's syndrome screening test). This will of course not happen immediately, but there are already several NHS trusts that have implemented NIPT at a local level (3). Suffice to say, NIPT is here to stay.

We at Antenatal Results and Choices (ARC), a UK charity that provides information and support to parents through antenatal testing and its consequences, can attest to the appetite for NIPT as we take numerous calls each day on our national helpline from women and their partners keen to gain the most accurate assessment of their risk of having a baby with Down's syndrome. Women clearly value having a test that will most often provide a result that means that they can avoid invasive diagnostic procedures that carry the risk of miscarriage.

However, the possible introduction of NIPT into a public health screening service has prompted ethical concerns. Some feel that because it involves no more than a simple blood test it will quickly become 'routinised' - women will hold out their arm blithely without thinking through the consequences. Some fear an increase in uptake, with an exponential rise in detection and then termination as women feel pressured to end pregnancies when given a diagnosis of aneuploidy. The author of a recent Washington Post online article was unequivocal: 'This will promote even more intensive de-selection of fetuses with Down syndrome, which in turn will negatively affect their position in society.' (4)

Our experience at ARC gives us confidence to allay some of those fears. While we do not know for sure what will happen when NIPT is available within the NHS, we can predict that the uptake of Down's syndrome screening nationally (currently around 66 percent) will increase. This will be partly due to more women opting-in because they feel decisions about invasive tests will be based on a more reliable evaluation of their individual risk. However, those for whom NIPT brings the news that the fetus is likely to be affected will still face the difficult decision about further testing. And it is not a given that all women will proceed to this next step.

We also need to be mindful that, however expectant parents receive a prenatal diagnosis, the decision about the future of a wanted pregnancy is never made lightly and will always be emotionally painful. We must always ensure that parents in this position receive high-quality care and non-judgmental support to enable them to proceed in a way that is right for them.

If we are confident that NIPT will improve detection rates, reduce the need for risky invasive procedures and achieve this in a cost-effective way, there is every reason to herald this technology as a welcome breakthrough. However, there are some caveats. The fact that NIPT has no risk to the pregnancy means that some women find it hard to give themselves permission to go directly for diagnostic testing, when their level of anxiety is such that they would really prefer to have a definitive yes or no answer. Furthermore, adding NIPT into the current screening programme creates an extra stage in the process, delaying the final diagnosis by a week or more. This will be a significant delay for women who decide to end their pregnancy and who would prefer to have the termination managed surgically rather than undergo medically induced delivery. The shortage of surgical expertise within the NHS means that this option is not available in most hospitals beyond 13 weeks. And, with fewer invasive procedures being undertaken, we will need to make sure that they are performed by clinicians who are able to maintain the requisite skills and competency.

My organisation is supportive of the NHS implementation of NIPT. It will end the current inequity, in which only those women who have means to pay benefit from the most effective screening. National oversight will ensure that provision is carefully co-ordinated and quality controlled. Fewer women will have to face the anxiety of invasive testing and the agony of losing a baby as a result of a diagnostic procedure. One thing NIPT will not change is the devastating impact of a confirmed prenatal diagnosis within the context of a wanted pregnancy, so we must be vigilant in employing the highest standards of care for expectant parents in this circumstance and support their individual choices.

SOURCES & REFERENCES
NHS Fetal Anomaly Screening Programme News, Autumn 2014 p3 | 
 
Current Genetic Medicine Reports. 2013;1(2):113-121 | 
 
St. George's University Hospitals (press release) | 01 June 2015
 
Washington Post | 16 June 2015
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

03 October 2016 - by Victoria Woodham 
The introduction of non-invasive prenatal testing in the NHS screening programme for pregnant women may seem like a no-brainer, but it is based on outdated ideas of what life is like for people with Down's syndrome and their families...
15 August 2016 - by Jane Fisher and Professor Lyn Chitty 
A central tenet of prenatal testing is to promote reproductive autonomy by providing women with information that can assist in pregnancy management. Bringing NIPT into the NHS will improve an established screening programme...
18 July 2016 - by Amina Yonis 
Non-invasive prenatal testing (NIPT) is improving all the time, and the tests may soon be offered to all pregnant women on the NHS. This event explored how to ensure that prospective mothers are properly counselled to make informed decisions about their pregnancy...
18 April 2016 - by Professor Caroline Ogilvie 
Press coverage of a recent study on mouse embryos speculates that termination of human pregnancies diagnosed with aneuploidy (a family of conditions including Down's syndrome) at prenatal diagnosis could be unnecessary, due to the ability of the fetus to 'heal itself'. In fact, the paper's findings are not relevant to aneuploidy detected at prenatal diagnosis...
25 January 2016 - by Vardit Ravitsky, Jessica Mozersky, Marsha Michie, Rayna Rapp, Megan Allyse, and Subhashini Chandrasekharan 
Since its introduction in 2011, the availability of non-invasive prenatal testing has been expanding globally and rapidly. The clinical introduction of NIPT has clear benefits for pregnant women, such as reducing the need for invasive testing. But, depending on local circumstances, it also raises varying challenges and opportunities...

08 June 2015 - by Kirsty Oswald 
Researchers say that a non-invasive prenatal test for Down's syndrome is ready to be introduced into the NHS...
13 April 2015 - by Kirsty Oswald 
Research shows that a new prenatal blood test for Down's syndrome outperforms current methods of screening...
10 March 2014 - by Dr Victoria Burchell 
A test using a simple blood sample from the expectant mother should soon be the primary screening method for Down's syndrome, according to a report from the Royal College of Obstetricians and Gynaecologists (RCOG)...
25 November 2013 - by Dr Felicity Boardman 
I was struck by a recent article that pushed to free Down's syndrome from inappropriate, negative language - that of 'disease', of 'risk' and of 'defect'...
04 November 2013 - by María Victoria Rivas Llanos 
A new method for prenatal testing for Down's syndrome will be tried out at Great Ormond Street Hospital for Children (GOSH), London....

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust
Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation